| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
Astilbin targets inflammatory and oxidative stress pathways. It enhances NRF2 activation. It suppresses TNF-α expression and NF-kB activation. Astilbin reduces activation of both T and B cells in lupus-prone mice. It up-regulates Stat3 inhibitor SCOSE3 expression in psoriatic lesions.
|
|---|---|
| ln Vitro |
Common dietary herbal flavonoid asstilbin can be found in a wide range of foods, including red wine, astragalus, sarsaparilla, and grapes. Cell growth produced by platinum was considerably suppressed and recovered by astelbin. Astilbin first stops the cisplatin-induced preservation of HEK-293 cells before dramatically reducing the buildup of reactive oxygen species (ROS) and attenuating ROS-induced activation of p53, MAPK, and AKT signaling cascades. In HEK-293 cells produced by cisplatin induction, astelbin efficiently reduces the formation of ROS by enhancing NRF2 activation and inhibiting the termination of antioxidant genes. Astilbin strongly suppresses the expression of cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), as well as the activation of NF-κB and tumor factor α (TNF-α). HEK-293 cells were treated with either 200 μM of Astilbin or 100 μM of CDDP to see how these treatments affected the proliferation of the kidney cells treated with CDDP. HEK-293 cells treated with astelbin showed a considerable improvement in CDDP-induced cell proliferation [1].
In vitro, Astilbin suppresses TNF-α expression and NF-kB activation. It enhances NRF2 activation. It has been shown to inhibit cisplatin-induced increases in apoptosis. Its antioxidant and anti-inflammatory activities have been characterized in various cell-based assays. |
| ln Vivo |
In order to investigate whether astelbin mitigates CDDP-induced nephrotoxicity in vivo, a mouse model of fast cisplatin nephrotoxicity was created. Much less weight was gained after receiving a single 8 mg/kg injection of CDDP than before the vacation. At a dose of 50 mg/kg, astelbin caused a much larger occurrence of this event. No discernible changes in body weight were observed in mice fed Astilbin alone. Mice treated with CDDP also had similar blood urea nitrogen (BUN) and serum myochrome (SCr) profiles. To conduct simulations, Astilbin was used. Both SCr and BUN were lowered throughout treatment. Astilbin's preventive efficacy against renal histopathological damage caused by CDDP was investigated using H&E staining. When compared to the CDDP group model, which showed severe kidney damage including renal tubular degeneration, bone marrow, renal tubule cystic dilatation, and proximity to focal heart disease, the kidney damage morphology of the dye and astelbin treated groups was normal. In comparison to the CDDP group, astelbin reduced renal damage and corresponding pathology scores. Astilbin therapy may be able to lessen CDDP-induced acute nephrotoxicity in mice receiving renal cell transplantation, as determined by TUNEL staining [1].
In vivo, Astilbin (50 mg/kg) increases renal glutathione (GSH) levels. It reduces activation of both T and B cells in lupus-prone mice. It inhibits keratinocyte over-proliferation in a mouse model of psoriasis. It possesses anti-arthritic and anti-diabetic nephropathy properties. |
| Enzyme Assay |
The activity of Astilbin can be assessed using cell-free assays to measure its antioxidant and anti-inflammatory properties. The DPPH radical scavenging assay and other antioxidant assays can be used. Its anti-inflammatory activity can be assessed by measuring the inhibition of TNF-α and NF-kB activation in cell-free systems.
|
| Cell Assay |
To evaluate the cellular effects of Astilbin, various cell lines are treated with the compound. The activation of NRF2 and its downstream targets is measured. The suppression of TNF-α expression and NF-kB activation is assessed. The effects on cell viability, proliferation, and inflammation are measured.
|
| Animal Protocol |
In vivo studies with Astilbin typically involve oral administration to animal models. In models of psoriasis, the compound's effects on skin inflammation and keratinocyte proliferation are assessed. In models of arthritis, its anti-arthritic effects are evaluated. In models of diabetic nephropathy, its renoprotective effects are assessed.
|
| ADME/Pharmacokinetics |
Astilbin has a molecular formula of C21H22O11 and a molecular weight of 450.39 g/mol. Its CAS number is 29838-67-3. It is a flavonoid compound. The purity is typically ≥97%. It should be stored according to the manufacturer's instructions.
|
| Toxicity/Toxicokinetics |
Specific toxicology data for Astilbin are not extensively detailed in the available literature. However, its use in animal models at effective doses suggests a degree of tolerability. As with all research compounds, standard safety precautions should be taken when handling Astilbin. It is intended for research use only and is not for human consumption.
|
| References | |
| Additional Infomation |
Astebenzin is a flavanone glycoside formed by the substitution of (+)-taxanthin at the 3-position by an α-L-rhamnosyl group via a glycosidic bond. It possesses free radical scavenging, anti-inflammatory, and plant metabolite activity. It is an α-L-rhamnosyl glycoside belonging to the 3'-hydroxyflavanone, tetrahydroxyflavanone, flavanone glycoside, monosaccharide derivative, and 4'-hydroxyflavanone classes. Functionally, it is related to (+)-taxanthin. It is the enantiomer of neoastebenzin. Astebenzin has been reported in Neolitsea aurata, Hymenaea martiana, and other organisms with relevant data. Astebenzin is a metabolite found or produced in Saccharomyces cerevisiae.
Astilbin is a natural flavonoid compound with antioxidant, anti-inflammatory, anti-arthritic, and anti-diabetic nephropathy properties. It enhances NRF2 activation and suppresses TNF-α expression and NF-kB activation. It reduces activation of T and B cells. It is a research tool for studying inflammation, oxidative stress, and autoimmune diseases. |
| Molecular Formula |
C21H22O11
|
|---|---|
| Molecular Weight |
450.3928
|
| Exact Mass |
450.116
|
| CAS # |
29838-67-3
|
| PubChem CID |
119258
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
801.1±65.0 °C at 760 mmHg
|
| Melting Point |
179 - 180 °C
|
| Flash Point |
282.9±27.8 °C
|
| Vapour Pressure |
0.0±3.0 mmHg at 25°C
|
| Index of Refraction |
1.748
|
| LogP |
2.97
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
676
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](OC3=CC(=CC(=C3C2=O)O)O)C4=CC(=C(C=C4)O)O)O)O)O
|
| InChi Key |
ZROGCCBNZBKLEL-MPRHSVQHSA-N
|
| InChi Code |
InChI=1S/C21H22O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-26,28-29H,1H3/t7-,15-,17+,18+,19+,20-,21-/m0/s1
|
| Chemical Name |
(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~222.03 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2203 mL | 11.1015 mL | 22.2030 mL | |
| 5 mM | 0.4441 mL | 2.2203 mL | 4.4406 mL | |
| 10 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
